TRUL has spent the past month climbing 35% — but the stock's most telling signal this week isn't in the price action, it's in who sold near the bottom and how loose the lending market remains despite that run.
The standout from recent insider data is CEO and founder Kimberly Rivers. In March she sold 2.5 million shares at roughly CAD 6.35, realising approximately USD 15.9 million. That transaction registered a low significance score, suggesting it was likely a pre-planned disposal rather than a tactical call against the stock — but the timing is notable. The stock has since more than doubled from those levels to CAD 16.14, meaning the founder exit preceded the bulk of the recovery. No insider buying appears in the trailing window to offset the sale, and other executives — the President, Chief Legal Officer and Chief Level Officers — received routine share awards in December but sold small parcels around the same time.
The lending market tells a relaxed story despite the sharp price move. Borrow availability is extremely loose, running at roughly 1,542% — meaning there are more than 15 shares available to borrow for every one already shorted. That reading has actually tightened sharply from around 4,270% in early June, which on paper looks dramatic but in absolute terms still signals an uncrowded borrow pool. Short interest remains negligible at just 0.27% of the free float, up 15% over the past month in share count terms but from a very low base — this is not a stock where bearish conviction has built in any meaningful way. Cost to borrow has drifted down about 16% on the week to 3.85%, and has oscillated in a range of roughly 2.3%–4.8% over the past six weeks, consistent with a name where the lending market is comfortable and unchallenged.
The ORTEX short score of 31.4 — ranking in the 84th percentile for short score rank — indicates the stock sits in relatively low-risk territory from a short-pressure standpoint. The days-to-cover figure of around 2.1 and an EV/EBITDA of roughly 7x put valuation in modest territory for a cannabis operator, and the price-to-book has expanded sharply over the past 30 days, rising nearly 0.75 turns as the stock re-rated. The PE multiple has jumped roughly 30 points over the same period, reflecting the speed of the move rather than earnings progress. Factor scores are mixed: EPS surprise ranks in just the 6th percentile, suggesting the company has historically disappointed on estimates, while the sector score sits at the median and the dividend score is low, as expected for a capital-intensive cannabis business still investing in its Florida-heavy footprint.
On the Street, analyst data is too stale to cite — the most recent consensus on file dates to mid-2023, well over two years ago — so the current sell-side picture is effectively a blank. That absence is itself informative: institutional coverage of U.S. cannabis multi-state operators listed on Canadian exchanges has thinned considerably, leaving price discovery largely to retail and event-driven participants. The largest declared institutional holder is Marex Group with just over 5% of shares, followed by Nomura at 4.2%, both of whom reported no change in their most recent filings.
Earnings are scheduled for August 5. The two most recent prints both triggered sharp negative reactions — the stock fell roughly 8% and 12% on the respective days, with five-day losses of 20% in each case. With the stock having recovered so sharply into that event, the shape of the next print — and specifically whether management addresses the CEO's March share sale — will be what the market is watching most closely.
See the live data behind this article on ORTEX.
Open TRUL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
